At WoundCon Fall, Jeanine Maguire, PhD, MPT, CWS introduced the use of electrical stimulation (e-stim) as a modality in wound healing. She discussed key terminology, current parameters for use in the ...
Basel, CH - (October 31, 2023) — Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.
In this interview, Dr. Windy Cole discusses the use of topical oxygen therapies and what processes oxygen help facilitate in wound healing. She indicates the etiologies this therapy can treat as well ...